List of Microbiome Companies in New Jersey - 5

Developed a highly multiplexed imaging technology for microbial detection, providing unparalleled speed, breadth, and flexibility.

Medical Diagnostic Laboratories, L.L.C. (MDL), founded in 1997, serves primarily as a reference laboratory for Polymerase Chain Reaction (PCR) based testing to physicians, laboratories and hospitals worldwide. MDL is a CLIA certified infectious disease laboratory with multiple state licenses specializing in PCR technology. Molecular diagnostic techniques, such as the PCR method, are considered to be the most sensitive and specific for the laboratory diagnosis of infectious diseases. MDL offers unique, non-invasive, highly stable specimen collection and transport platforms, such as the OneSwab®, UroSwab® and NasoSwab®. These platforms enable MDL to offer a variety of PCR based tests from a single swab with high sensitivity and specificity. MDL specializes in high complexity, state-of-the-art, automated DNA-based molecular analyses. By using molecular techniques, MDL is able to provide clinicians from many different specialties valuable tailored diagnostic information to assist in the detection, diagnosis, evaluation, and treatment of viral, fungal, and bacterial infections. For example, the unique testing MDL offers for the specialties of Urology and Gynecology enables the detection of multiple pathogens as well as certain drug resistance profiles from a single swab by PCR. MDL's primary focus is in the field of infectious disease testing for Urology, Obstetrics and Gynecology, Respiratory Infectious diseases, Vector-borne diseases, Mycology and Pharmacogenomics. MDL is comprised of experts in the fields of Molecular Biology, Immunology, Virology, Microbiology, Mycology, Pharmacogenomics, Antimicrobial Resistance and Oncology. In addition to developing and validating new clinical diagnostic tests, the Research and Development Department also publishes research projects in peer-reviewed journals, presents scientific information at international symposia, and performs contractual research work for major commercial, governmental, and academic organizations.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Founded in 1895, Nexira is a family owned company who built its reputation as the world leader in acacia gum. Today Nexira is a global leader in natural ingredients and botanical extracts for food, nutrition, and dietary supplements. Our ingredients are perfectly suitable for the formulation of clean label products. Nexira manufactures in France a wide range of natural ingredients with recognized health benefits, such as Fibregum™ an all-natural, organic and GMO-free source of soluble dietary fiber. Nexira's portfolio for food industry includes a large range of branded natural acacia gum ingredients with exceptional functional properties (Emulsifiers & stabilizers, coating agents, texturizers, encapsulating agents…). Nexira's portfolio for supplement industry includes premium nutraceuticals, strongly supported with scientific & marketing supports, for digestive health, weight management, sports nutrition, joint health and men & women’s health.

Notitia ("NO-TEE-SHA") means "data" in Latin. We are a microbiome company that applies a data-driven approach to develop innovative products for the ecological restoration of a healthy gut microbiome.  Our mission is to promote health by protecting and/or restoring the Foundation Guild™ of the gut microbiome. Our vision is to maximize everyone's healthspan by keeping their gut microbiome to the healthiest possible status for the longest possible time. The work of Dr. Liping Zhao, co-founder of Notitia, shows that a healthy gut microbiome is dominated by a specific group of beneficial bacteria named the "Foundation Guild." The Foundation Guild™ not only produces beneficial compounds essential to human health but also creates an environment that can suppress the overgrowing pathogens. Restoration and maintenance of the Foundation Guild™ are fundamental to improve health and wellness in patients with unmet medical needs and the generally healthy population. Notitia has developed a revolutionary Foundation Guild™ R&D platform which consists of three technologies: identification, isolation & preservation, and nutritional formulas to support the Foundation Guild™ bacteria. Notitia has created several products based on the Foundation Guild™ R&D platform for patients as well as for the generally healthy population. Foundation Guild™ Wellness Program: a monthly subscription service that provides: 1. Guild:Plus microbiome nutrition 2. Guild:Health data tracking portal 3. Guild:Quest microbiome test kit 4. Guild:Save bio-banking 5. Guild:Pro personalized family-based probiotics. Foundation Guild™ Clinical Program: 1. NBT-NM108, a botanical drug for promoting the Foundation Guild, currently available in a phase 2 trial for COVID-19 and expanded access programs. Additional trials for MS, DKD, Cancer, and Parkinson's will be available by Dec 2021. 2. NBT-BM306, a live biotherapeutic product for restoring the Foundation Guild. Phase 1 trial will be available by Dec 2021.